Potassium gluconate and Cerebral haemorrhage - a phase IV clinical study of FDA data


Cerebral haemorrhage is found among people who take Potassium gluconate, especially for people who are male, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Potassium gluconate and have Cerebral haemorrhage. It is created by eHealthMe based on reports of 2,236 people who have side effects when taking Potassium gluconate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 27, 2022

2,236 people reported to have side effects when taking Potassium gluconate.
Among them, 13 people (0.58%) have Cerebral haemorrhage.

What is Potassium gluconate?

Potassium gluconate has active ingredients of potassium. It is often used in hypokalemia. eHealthMe is studying from 2,319 Potassium gluconate users for its effectiveness, alternative drugs and more.

What is Cerebral haemorrhage?

Cerebral haemorrhage (bleeding within the brain) is found to be associated with 1,915 drugs and 1,453 conditions by eHealthMe.

Number of Potassium gluconate and Cerebral haemorrhage reports submitted per year:

Could Potassium gluconate cause Cerebral haemorrhage?

Time on Potassium gluconate when people have Cerebral haemorrhage *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Cerebral haemorrhage when taking Potassium gluconate *:

  • female: 40 %
  • male: 60 %

Age of people who have Cerebral haemorrhage when taking Potassium gluconate *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Potassium gluconate *:

  1. Zolpidem: 8 people, 61.54%
  2. Pyridoxine: 8 people, 61.54%
  3. Prazepam: 8 people, 61.54%
  4. Pantoprazole: 8 people, 61.54%
  5. Insulin: 8 people, 61.54%
  6. Potassium Phosphate: 3 people, 23.08%
  7. N-Acetylcysteine: 3 people, 23.08%
  8. Xarelto: 1 person, 7.69%
  9. Vesicare: 1 person, 7.69%
  10. Olmesartan Medoxomil: 1 person, 7.69%

Common side effects people have besides Cerebral haemorrhage *:

  1. Wolff-Parkinson-White Syndrome (a heart condition in which there is an abnormal extra electrical pathway of the heart): 8 people, 61.54%
  2. Low Birth Weight Baby: 8 people, 61.54%
  3. Anal Stenosis (narrowing of the anal sphincter and opening): 8 people, 61.54%
  4. Asthma: 8 people, 61.54%
  5. Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 8 people, 61.54%
  6. Dacryostenosis Acquired (obstruction of the nasolacrimal duct-acquired): 8 people, 61.54%
  7. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 8 people, 61.54%
  8. Emotional Disorder: 8 people, 61.54%
  9. Foetal Distress Syndrome (altered heart rate or rhythm and leading tocompromised blood flow or changes in blood chemistry of foetus): 8 people, 61.54%
  10. Haemangioma (noncancerous, abnormally dense collections of dilated small blood vessels that may occur in the skin or internal organs): 8 people, 61.54%

Common conditions people have *:

  1. Gastric Ulcer (stomach ulcer): 4 people, 30.77%
  2. High Blood Pressure: 4 people, 30.77%
  3. Pulmonary Oedema (fluid accumulation in the lungs): 3 people, 23.08%
  4. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 23.08%
  5. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 23.08%
  6. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 23.08%
  7. Cardiac Failure: 3 people, 23.08%
  8. Constipation: 3 people, 23.08%
  9. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 23.08%
  10. Diabetes: 3 people, 23.08%

* Approximation only. Some reports may have incomplete information.

Do you take Potassium gluconate and have Cerebral haemorrhage?

Check whether Cerebral haemorrhage is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Cerebral haemorrhage and when was it recovered:

Expand to all the drugs that have ingredients of potassium:

Alternative drugs to, pros and cons of Potassium gluconate:

Common Potassium gluconate side effects:

Browse all side effects of Potassium gluconate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Cerebral haemorrhage treatments and more:

COVID vaccines that are related to Cerebral haemorrhage:

Common drugs associated with Cerebral haemorrhage:

All the drugs that are associated with Cerebral haemorrhage:

Common conditions associated with Cerebral haemorrhage:

All the conditions that are associated with Cerebral haemorrhage:

How the study uses the data?

The study uses data from the FDA. It is based on potassium (the active ingredients of Potassium gluconate) and Potassium gluconate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: